GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development
Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth...
NYSE: BHVN
Biohaven Acquires Global Rights for Dual TYK2/JAK1 Inhibitor BHV-8000 from Highlightll
US-based Biohaven Ltd. (NYSE: BHVN) has announced the acquisition of global rights, excluding China regions,...